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Abstract 
Despite cumulative evidence supporting the idea that gross total resection (GTR) 
contributes to prolonged survival of patients with glioblastoma (GBM), the survival 
outcome of such patients remains unsatisfactory. To develop more effective 
postoperative therapeutic strategies for patients who underwent GTR, identification of 
prognostic factors influencing survival is urgently needed. Here we retrospectively 
analyzed prognostic factors for patients who underwent GTR of newly diagnosed GBM, 
with a particular focus on the influence of the subventricular zone (SVZ) as the tumor 
location. Forty-eight consecutive patients with newly diagnosed GBM who underwent 
GTR during the initial operation were investigated. Tumor involvement of the SVZ was 
significantly associated with overall survival (OS). The SVZ-positive group had a 
significantly shorter median OS of 12.2 months, compared to 34.9 months for the SVZ-
negative group. The occurrence of leptomeningeal dissemination was significantly 
influenced by tumor involvement of the SVZ, but was not significantly influenced by 
ventricular opening during surgery. We observed a statistically significant difference in 
OS according to radiation modality. The median OS was 36.9 months for patients 
treated with high-dose proton beam therapy, compared with 26.2 months for patients 
treated with conventional radiotherapy. We demonstrated that tumor involvement of the 
SVZ was associated with poor survival of patients who underwent GTR of newly 
diagnosed GBM, suggesting the potential need for therapeutic strategies that 
specifically target tumors in the SVZ. Further prospective studies to evaluate whether 
radiotherapy targeting the SVZ improves survival of patients with tumor involvement of 
the SVZ who had undergone GTR are warranted. 
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Introduction 
In the last several decades, evidence has been accumulating that supports the notion 
that gross total resection (GTR) leads to prolonged survival of patients with 
glioblastoma (GBM)[1-4]. Therefore, to achieve GTR, many technologies such as 
intraoperative neuronavigation systems, 5-aminolevulinic acid, and intraoperative 
magnetic resonance imaging (MRI) have been introduced. However, the survival 
outcome of patients with GBM who underwent GTR remains unsatisfactory, with a 
median survival of 15.2–18.8 months[2, 3, 5]. These results suggest that further efforts 
should be made to develop more effective postoperative therapeutic strategies for GBM 
after GTR.  
Because individual patient survival varies, identification of prognostic factors for 
shortened or prolonged survival is urgently needed for the development of appropriate 
therapeutic strategies. To date, a number of studies have analyzed the prognosis of 
patients with newly diagnosed GBM, and several different factors (e.g., age, 
preoperative performance status, tumor location, extent of resection, radiotherapy, and 
chemotherapy with temozolomide) have been identified as potential prognostic 
factors[5-7]. We recently demonstrated the prognostic potential of high-dose particle 
radiotherapies for newly diagnosed GBM[8-10]. However, the prognostic factors for 
patients who underwent GTR have not been studied in detail. 
Previous studies suggest that the heterogeneity in survival and recurrence patterns 
in patients with GBM may be related to the presence of neural stem cells within the 
subventricular zone (SVZ) [11, 12]. Furthermore, recent studies demonstrated that 
GBMs involving the SVZ are associated with earlier recurrence and poor survival[11, 
13, 14]. Those studies mainly analyzed patients who did not undergo GTR (the ratio of 
patients who underwent GTR varied from 29 to 35%), and thus, the prognostic value of 
SVZ involvement in patients who underwent GTR remains unclear. 
The purpose of the present study was to identify prognostic factors for patients who 
underwent GTR of newly diagnosed GBM. Specifically, we focused on the influence of 
tumor involvement of the SVZ. 
Materials and Methods 
From July 2006 to June 2015, 172 consecutive patients with newly diagnosed GBM 
were treated at the University of Tsukuba Hospital. Of these 172 patients, 48 underwent 
GTR of their tumor at the initial operation. The diagnosis of GBM was determined 
histopathologically based on the classification system of the World Health Organization. 
Patients with prior lower grade glioma or previous tumor resection were excluded from 
the analysis. GTR, which is defined as complete removal of the contrast-enhancing 
portion of the tumor, was confirmed by postoperative MRI that was obtained as soon as 
possible after surgery within 72 hours. We retrospectively reviewed the clinical and 
operative charts and radiographic images of these 48 patients. 
All patients received radiotherapy with or without chemotherapy. The patients with 
GBM treated at our institute received one of two postoperative radiotherapy protocols. 
As conventional radiotherapy (CRT), daily photon radiotherapy of 2.0 Gy was 
administered five times per week, amounting to a total overall dose of 60.0 Gy. For 
high-dose proton beam therapy (PBT), a total dose of 96.6 GyE as hyperfractionated 
concomitant boost PBT was prescribed for the area of the surgical cavity seen on MRI 
plus a 5-mm margin. A 15-mm margin around the surgical cavity and a 20-mm margin 
around the region of perifocal edema were irradiated at doses of 73.5 GyE and 50.4 
GyE, respectively. 
Tumor involvement of the SVZ was defined if the contrast-enhancing lesion 
contacted the lateral walls of the lateral ventricle[11, 15]. The O6-methylguanine-DNA-
methyltransferase (MGMT) methylation status was determined by methylation-specific 
PCR. Isocitrate dehydrogenase-1 (IDH1) R132H mutation status was determined by 
immunohistochemistry using IMab-1[16]. 
Statistical analyses were performed using SPSS software (version 22; SPSS, Inc.). 
Overall survival (OS), defined as the time from surgery until death, was used to 
investigate the prognostic value of the analyzed variables. Survival probabilities were 
calculated using the Kaplan-Meier method, and differences among patient groups were 
evaluated using the log-rank test. The difference in categorical variables was evaluated 
using the Fisher’s exact test. The difference in continuous variables was evaluated using 
the non-paired Student’s t-test. A value of p < 0.05 was considered statistically 
significant in all analyses.  
Results 
The demographic, clinical, and treatment characteristics of the 48 patients are 
shown in Table 1. The mean age of the patients was 56.9 years (range, 14-76 years). 
Twenty-four patients were males, and 24 were females. The median Karnofsky 
performance status was 80 (range, 40-100). Nineteen (39.6%) patients had tumors 
involving the SVZ (SVZ-positive), and 29 (60.4%) had tumors located outside the SVZ 
(SVZ-negative). In 34 (70.8%) patients, the lateral ventricle was opened during surgery. 
Thirty-one (64.6%) patients received CRT, and 17 (35.4%) received PBT. Forty-two 
(87.5%) patients received concomitant chemotherapy with temozolomide, two patients 
(4.2%) received chemotherapy with nimustine hydrochloride alone, one patient (2.1%) 
received chemotherapy with a combination regimen of procarbazine, nimustine 
hydrochloride, and vincristine, and three patients (6.3%) received no chemotherapy. In 
three (6.3%) patients, biodegradable carmustine wafers were implanted during surgery. 
Nine (18.8%) patients received bevacizumab upon recurrence. Thirty-three (68.8%) 
patients developed recurrences during the follow-up period, of which 23 (69.7%) 
patients developed local or distant recurrences, and 10 (30.3%) developed 
leptomeningeal dissemination. 
The median OS for all patients was 28.6 months (95% confidence interval, 18.0–
39.1 months). The 1- and 2-year survival rates were 78.3% and 65.8%, respectively. 
Age, gender, Karnofsky performance status, tumor involvement of the SVZ, ventricular 
opening during surgery, MGMT methylation status, R132H mutant IDH1 expression, 
radiation modality, temozolomide, biodegradable carmustine wafer implantation, and 
bevacizumab administration upon recurrence were examined as prognostic factors for 
survival using univariate analysis. The results of the analysis based on the Kaplan-Meier 
method and the log-rank test are summarized in Table 2. Tumor involvement of the SVZ 
was significantly associated with OS. The SVZ-positive group had a significantly 
shorter median OS of 12.2 months compared to 34.9 months for the SVZ-negative 
group (p = 0.007) (Fig. 1A). We also observed a statistically significant difference in OS 
according to radiation modality. The median OS was 36.9 months for patients treated 
with PBT compared with 26.2 months for those treated with CRT (p = 0.015) (Fig. 1B). 
Regarding other factors, age was the only significant factor associated with OS. 
Although we observed tendencies for an association between the MGMT methylation 
status or R132H mutant IDH1 expression and OS, these tendencies did not reach 
statistical significance. In relation to the association between tumor involvement of the 
SVZ and other factors, age, ventricular opening during surgery, radiation modality, and 
biodegradable carmustine wafer implantation were significantly correlated. The SVZ-
positive group included more elderly patients than the SVZ-negative group. In the SVZ-
positive group, ventricular opening during surgery was likely performed, whereas PBT 
and biodegradable carmustine wafer implantation were less likely to be undertaken. 
With regard to the association between radiation modality and other factors, no factors 
were significantly correlated other than tumor involvement of the SVZ. The occurrence 
of leptomeningeal dissemination was significantly influenced by tumor involvement of 
the SVZ, but was not significantly influenced by ventricular opening during surgery.  
Discussion 
In the present study, we identified the prognostic significance of tumor location with 
involvement of the SVZ and high-dose radiotherapy using PBT in consecutive patients in 
our institution who underwent GTR of newly diagnosed GBM. In addition, tumor 
involvement of the SVZ was significantly associated with leptomeningeal dissemination 
at recurrence. 
Several previous studies demonstrated a correlation between tumor involvement of 
the SVZ and poor survival in patients with both newly diagnosed and recurrent GBM[14, 
17, 18]. Furthermore, an association between distant and multifocal recurrence patterns 
in GBM and tumor involvement of the SVZ has been reported[12, 15]. Consistent with 
those previous reports in which patients who did not undergo GTR were mainly analyzed, 
we demonstrated the prognostic significance of tumor involvement of the SVZ, even in a 
series of patients who underwent GTR of newly diagnosed GBM.  
Although the underlying cause of aggressive GBM behavior and tumor involvement 
of the SVZ is not yet completely understood, several hypotheses have been proposed. 
Lim et al. suggested that tumor cells near the SVZ may be closely related to neural stem 
cells, and the tumor cells may be highly migratory and invasive[12]. Chaichana et al. 
proposed another hypothesis that the SVZ region may have a different cellular 
environment that is more conducive to tumor proliferation and invasion[14].  
In the present study, ventricular opening during surgery was not correlated with 
leptomeningeal dissemination at recurrence or poor survival, consistent with previous 
reports[15, 19, 20]. Our results suggested that surgical difficulty based on close proximity 
to subcortical fibers and critical neurological tissue, as well as surgical intervention 
including ventricular opening along with tumor involvement of the SVZ, were less likely 
to contribute to poor survival than the biological nature of tumor cells and the anatomical 
environment of the SVZ. However, the molecular basis of this clinical phenomenon 
remains unclear. 
The potential benefit of high-dose particle radiotherapy using hyperfractionated, 
concomitant boost PBT for patients with newly diagnosed GBM has been demonstrated 
in several previous studies[9, 10, 21, 22]. In those studies, only a selected population of 
patients who met the eligibility criteria were enrolled, and patients who did not undergo 
GTR were mainly analyzed. Our previous reports showed that high-dose, 96.6-GyE, 
concentric PBT, which was the same treatment protocol as in the present study, has high 
potential to improve survival in GBM patients with residual tumor after surgical 
resection[9, 22]. In our PBT protocol, the residual tumor plus a 5-mm margin was 
irradiated with 96.6 GyE, and in cases without residual tumor, the surgical cavity as seen 
on MRI plus a 5-mm margin was irradiated with 96.6 GyE. In the present study, we 
demonstrated the potential survival benefit of high-dose, 96.6-GyE, concentric PBT 
compared to CRT, even in cases without residual tumor. 
To overcome the negative influence of tumor involvement of the SVZ on survival, 
alternative approaches specifically targeting the SVZ will be needed. Several 
retrospective studies have analyzed the relationship between the radiation dose to the SVZ 
and the outcome of patients with newly diagnosed GBM [23-26]. Those studies were 
designed based on the hypothesis that therapy targeting GBM stem cells from the SVZ 
may be beneficial because these cells potentially initiate or contribute to GBM and worsen 
patient outcome. Thus, for comparison, the patients analyzed in those studies were not 
restricted to patients with tumor involvement of the SVZ. In three previous reports, an 
association between a higher radiation dose to the ipsilateral SVZ and significantly 
improved OS, progression-free survival, or both was demonstrated[23, 25, 26]. On the 
contrary, a conflicting report showed no association between the radiation dose to the 
ipsilateral SVZ and survival[24]. Although whether a higher radiation dose to the SVZ is 
generally beneficial for the outcome of GBM patients remains controversial, Chen et al. 
stated that a higher radiation dose to the ipsilateral SVZ positively impacts the survival 
of only patients who had undergone GTR[23]. Particularly for GBM patients with tumor 
involvement of the SVZ, radiotherapy targeting the SVZ after GTR may play a critical 
role in survival. The potential benefit of high-dose radiotherapy using PBT in terms of 
the dose to the SVZ has not been investigated well. Our study has some limitations. The 
potential confounding between tumor involvement of the SVZ and high-dose 
radiotherapy using PBT may influence our results because PBT was less likely to be 
undertaken in the SVZ-positive group. However, patients with tumor involvement of the 
SVZ treated with PBT tended to survive longer than those treated with CRT, although 
these tendencies did not reach statistical significance due to the relatively small sample 
size. Also, we could not evaluate the association between the dose of PBT to the SVZ and 
survival of patients with tumor involvement of the SVZ because of the relatively small 
sample size. Further evaluation will be needed to determine whether radiotherapy 
targeting the SVZ including PBT has the potential to increase survival in patients with 
tumor involvement of the SVZ who had undergone GTR. 
In conclusion, we demonstrated that tumor involvement of the SVZ was associated 
with poor survival of patients who underwent GTR of newly diagnosed GBM, suggesting 
the potential need for therapeutic strategies that specifically target the SVZ. We also 
demonstrated that high-dose PBT for the surgical cavity after GTR has a potential benefit 
on survival. Further prospective studies are warranted to evaluate whether radiotherapy 
targeting the SVZ including PBT improves survival of patients with tumors involving the 
SVZ who had undergone GTR. 
  
Figure Captions 
Fig. 1: The results of univariate analysis based on the Kaplan-Meier method 
A: Kaplan-Meier estimates of overall survival according to tumors involving the SVZ 
or not. B: Kaplan-Meier estimates of overall survival according to radiation modality. 
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Table 1
Characteristics No. of patients %
Age (yrs)
  Mean ± SD 56.9 ± 13.2
  Range 14-76
Gender
  Male 24 50.0
  Female 24 50.0
KPS
  100 3 6.3
  90 18 37.5
  80 12 25.0
  70 7 14.6
  60 2 4.2
  50 3 6.3
  40 3 6.3
Tumor involvement of SVZ
  + 19 39.6
  - 29 60.4
Ventricular opening during surgey
  + 34 70.8
  - 14 29.2
MGMT methylation status
  methylated 15 31.3
  unmethylated 29 60.4
R132H mutant IDH1 expression
  positive 8 16.7
  negative 39 81.3
Radiation modality
  CRT 31 64.6
  PBT 17 35.4
Concomitant temozolomide
  + 42 87.5
  - 6 12.5
Biodegradable carmustine wafer
  + 3 6.3
  - 45 93.8
Bevacizumab upon recurrence
  + 9 18.8
  - 39 81.3
SD: standard deviation, KPS: Karnofsky performance status,
SVZ: subventricular zone, MGMT: O6-methylguanine-DNA-
methyltransferase,
IDH1: Isocitrate dehydrogenase-1, CRT: conventional radiotherapy,
PBT: proton beam therapy.
Demographic, clinical, and treatment characteristics
 of the 48 patients analyzed in this study
Table 2
Overall survival  analysis
Variable Median Survival(mos) p Value (log-rank)
Age <0.001
  ≥70 yrs 10.1
  <70 yrs 34.9
Gender 0.837
  male 26.8
  female 34.4
KPS 0.422
  ≥80 28.6
  <80 26.8
Tumor involvement of SVZ 0.007
  SVZ-positive 12.2
  SVZ-negative 34.9
Ventricular opening during surgery 0.804
  + 26.8
  - 34.9
MGMT methylation status 0.150
  methylated 36.9
  unmethylated 26.2
R132H mutant IDH1 expression 0.169
  positive 36.9
  negative 26.8
Radiation modality 0.015
  CRT 26.2
  PBT 36.9
Concomitant temozolomide 0.785
  + 28.6
  - 10.5
Biodegradable carmustine wafer 0.689
  + 10.1
  - 28.6
Bevacizumab upon recurrence 0.418
  + 35.7
  - 26.8
KPS: Karnofsky performance status, SVZ: subventricular zone,
MGMT: O6-methylguanine-DNA-methyltransferase, IDH1: Isocitrate dehydrogenase-1,
CRT: conventional radiotherapy,  PBT: proton beam therapy.

